Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (161-170 of 437) with videos related to

Pageof 44
Sort By:
Clinical and Translational Science|September 28, 2021
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)Solange Peters, Peter R Galle, Coen A Bernaards, et al.
ESMO Open|June 26, 2020
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancerAntonio Passaro, Alfredo Addeo, Christophe Von Garnier, et al.
Clinical Lung Cancer|February 22, 2015
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential BiomarkerRodryg Ramlau, Michael Thomas, Silvia Novello, et al.
Cancers|March 6, 2021
History of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the LiteratureChiara Lazzari, Aurora Mirabile, Alessandra Bulotta, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 17, 2014
The tissue is the issue: improved methylome analysis from paraffin-embedded tissues by application of the HOPE techniqueSebastian Marwitz, Julia Kolarova, Martin Reck, et al.
Clinical Lung Cancer|January 22, 2013
A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancerWolfgang H W Schuette, Andreas Gröschel, Martin Sebastian, et al.
Histology and Histopathology|July 6, 2023
TRIM11 expression in non-small cell lung cancer is associated with poor prognosisChristiane Kuempers, Tobias Jagomast, Finn-Ole Paulsen, et al.
Pneumologie (Stuttgart, Germany)|November 17, 2025
[Correction: White paper on identification, information, and eligibility assessment of potential participants in lung cancer screening in Germany]Torsten Gerriet Blum, Jens Vogel-Claussen, Hans Hoffmann, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2025
Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysisFabian Acker, Martin Reck, Daniel Martin, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|August 7, 2023
Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150Anika Mang, Wei Zou, Vinzent Rolny, et al.
Pageof 44

Showing results (161-170 of 437) with videos related to

Sort By:
Pageof 44
Clinical and Translational Science|September 28, 2021
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)Solange Peters, Peter R Galle, Coen A Bernaards, et al.
ESMO Open|June 26, 2020
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancerAntonio Passaro, Alfredo Addeo, Christophe Von Garnier, et al.
Clinical Lung Cancer|February 22, 2015
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential BiomarkerRodryg Ramlau, Michael Thomas, Silvia Novello, et al.
Cancers|March 6, 2021
History of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the LiteratureChiara Lazzari, Aurora Mirabile, Alessandra Bulotta, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 17, 2014
The tissue is the issue: improved methylome analysis from paraffin-embedded tissues by application of the HOPE techniqueSebastian Marwitz, Julia Kolarova, Martin Reck, et al.
Clinical Lung Cancer|January 22, 2013
A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancerWolfgang H W Schuette, Andreas Gröschel, Martin Sebastian, et al.
Histology and Histopathology|July 6, 2023
TRIM11 expression in non-small cell lung cancer is associated with poor prognosisChristiane Kuempers, Tobias Jagomast, Finn-Ole Paulsen, et al.
Pneumologie (Stuttgart, Germany)|November 17, 2025
[Correction: White paper on identification, information, and eligibility assessment of potential participants in lung cancer screening in Germany]Torsten Gerriet Blum, Jens Vogel-Claussen, Hans Hoffmann, et al.
European Journal of Cancer (Oxford, England : 1990)|February 2, 2025
Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysisFabian Acker, Martin Reck, Daniel Martin, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|August 7, 2023
Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150Anika Mang, Wei Zou, Vinzent Rolny, et al.
Pageof 44